Application of compound moxa tablet in preparation of medicine for treating diabetic nephropathy
By preparing and applying compound Aila tablets, the problem of the ineffective treatment of diabetic nephropathy in existing technologies has been solved, and the effects of significantly reducing blood indicators, improving renal oxidative stress, and alleviating kidney damage have been achieved.
Patent Information
- Application Number
- CN202411054217.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
AI Technical Summary
Current technology has not effectively utilized compound ALA tablets to treat diabetic nephropathy, and there is a lack of pharmacodynamic research and application of its effects on improving diabetic nephropathy.
The preparation method of Compound Aila Tablets was adopted, including ethanol extraction and concentration of medicinal materials such as Anachia root, Bletilla striata, Epimedium, Rhodiola rosea, Cuscuta chinensis, Polygonatum odoratum, Lycium barbarum, and Cinnamomum cassia, combined with saffron powder, to make tablets. The tablets were used in a rat model of diabetic nephropathy induced by a high-sugar, high-fat diet combined with low-dose STZ to observe the efficacy.
Compound Aila tablets significantly reduced serum creatinine, blood urea nitrogen, uric acid, total cholesterol and triglyceride levels in diabetic nephropathy rats, improved renal oxidative stress capacity, improved nephropathy, and alleviated kidney damage caused by diabetic nephropathy.
Smart Images

Figure CN118976077A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the use of a compound Aila tablet in a drug for treating diabetic nephropathy. The compound, when administered to rats with diabetic nephropathy caused by a high-sugar and high-fat diet combined with a low-dose intraperitoneal injection of streptozotocin (STZ), shows the effects of reducing creatinine, urea nitrogen, uric acid, total cholesterol, triglycerides and rat kidney weight ratio, and enhancing kidney oxidative stress, thereby improving kidney damage in rats with diabetic nephropathy and achieving the effect of treating diabetic nephropathy. Background Art
[0002] Diabetes mellitus (DM) is a metabolic disease characterized by high blood sugar and has become a major chronic disease worldwide. Diabetic nephropathy (DN) is the most common complication of diabetes and the main cause of end-stage renal disease. In recent years, the incidence of diabetes has increased dramatically. According to data from the International Diabetes Federation in 2019, the number of people with diabetes worldwide was 463 million in 2019, and it is expected to reach 700 million by 2045. It is estimated that 30%-40% of diabetics will develop diabetic nephropathy, of which about half will develop end-stage renal disease (ERSD). Because patients have complex metabolic disorders, the mortality rate of patients with diabetic nephropathy is much higher than that of patients with kidney disease without diabetes. In terms of social public health, diabetic nephropathy has a very important impact on society.
[0003] AiLa Tablets are guided by the theory of Uyghur medicine. The Chinese medicine master Mr. Bahe Yusup used the two prescriptions of Puruniya Mi Gao recorded in the ancient Uyghur medical book "Baidyi Pharmacy" and Aibijia Diwaer Pills recorded in "Kalabadin Kadizhi" as the blueprint. Combining many years of clinical experience, the two prescriptions were added and subtracted to form a combination. It has the effects of warming the kidney and strengthening yang, nourishing essence and consolidating astringency, and consolidating essence and reducing urine. Researcher Aji Aikebai Isa led the team to optimize the prescription and conduct pharmacodynamic research on it, and determined a formula composed of anaqi root, central Asian bletilla, epimedium, rhodiola rosea, dodder seed, polygonatum, wolfberry, cinnamon, saffron, etc. The pharmacodynamic results showed that it has aphrodisiac effects and can treat erectile dysfunction. It has been granted an invention patent (ZL201610365729.8), and the compound Aila tablets have also obtained a new drug clinical approval certificate (notification number: 2021LP01651), but its application in the treatment of diabetic nephropathy has not yet been reported.
[0004] The present invention studies the efficacy of Compound Aila Tablets in treating diabetic nephropathy, discovers new uses of Compound Aila Tablets, and provides support for the research and development of new clinical indications of Compound Aila Tablets. At the same time, it further reveals the scientific connotation of Compound Aila Tablets, and provides a scientific basis for further improving its popularity and exploring ethnic medicinal resources. Summary of the invention
[0005] The object of the present invention is to provide a compound Aila tablet for use in the preparation of a drug for treating diabetic nephropathy. The compound Aila tablet is composed of Anachia root, Bletilla striata, Epimedium, Rhodiola rosea, Cuscuta chinensis, Polygonatum odoratum, Lycium barbarum, Cinnamon bark, Crocus saffron, etc. The remaining Chinese medicinal materials except saffron are refluxed by 50% ethanol, and the extract is concentrated and dried to powder, and then mixed with saffron medicinal material fine powder to obtain the compound Aila tablet. Animal experiments show that the compound Aila tablet has the effect of reducing the content of creatinine, urea nitrogen, uric acid, triglycerides and total cholesterol in the blood; improving the kidney's oxidative stress capacity and improving kidney lesions caused by high sugar damage, and can be used in drugs for treating diabetic nephropathy.
[0006] The invention discloses use of the compound Aila tablets in preparing medicine for treating diabetic nephropathy.
[0007] The use of a compound Aila tablet of the present invention in preparing a drug for treating diabetic nephropathy, and the preparation method of the compound Aila tablet is as follows:
[0008] a. According to the formula in patent 201610365729.8, weigh the raw medicinal materials of anacardia root, Bletilla striata, Epimedium, Rhodiola rosea, Cuscuta australis, Polygonatum odoratum, Lycium barbarum and cinnamon, and use 16 times the amount of 50% ethanol for heating and reflux extraction once, extract for a total of 2h, and collect the extract;
[0009] b. The extract in step a was filtered through a 120-mesh stainless steel mesh, and the filtrate was concentrated under reduced pressure at a temperature of 60°C, -0.08MPa, to a relative density of 1.1, and then transferred to a vacuum drying oven at a temperature of 60°C, -0.08MPa to obtain an extract, which was then crushed by a universal grinder and passed through a 100-mesh oscillating sieve to obtain a subdivided extract;
[0010] c. The saffron was crushed and mixed with the extract powder obtained in step b through a 100-mesh sieve to obtain a compound Aila tablet extract;
[0011] d. The Aila tablet extract obtained in step c is prepared into tablets with povidone K90 as a binder and cross-linked sodium carboxymethyl cellulose as a disintegrant to obtain compound Aila tablets.
[0012] The use of a compound Aila tablet described in the present invention in the preparation of a drug for treating diabetic nephropathy. Animal experiments were conducted to verify the efficacy of the compound Aila tablet in treating diabetic nephropathy; a diabetic nephropathy rat model was induced by a high-sugar and high-fat diet combined with a low-dose intraperitoneal injection of streptozotocin (STZ), and the fluctuations in rat body weight and fasting blood sugar were observed; blood sugar-related indicators, kidney-related indicators, and blood lipid-related indicators in rat blood; rat kidney biochemical indicators, kidney antioxidant indicators, and kidney pathology. Statistical analysis was used to deeply analyze the improvement effect of the compound Aila tablet on diabetic nephropathy based on the data of rat body weight, fasting blood sugar, blood sugar-related indicators, kidney-related indicators, blood lipid-related indicators, kidney biochemical indicators, kidney antioxidant indicators, and kidney pathology in the control group, model (high-sugar and high-fat diet combined with STZ modeling) group, and drug-treated group. The results showed that after the compound Aila tablets acted on diabetic rats, the weight loss of rats caused by diabetic nephropathy was alleviated, and the blood sugar level of diabetic nephropathy rats was stabilized; the renal index levels of blood creatinine, urea nitrogen and uric acid in diabetic nephropathy rats were reduced, and the kidney-to-weight ratio of rats was reduced; total cholesterol and triglycerides were reduced. The levels of reduced glutathione, catalase, and superoxide dismutase in the kidneys were increased, the level of malondialdehyde in the kidneys was reduced, and the antioxidant activity of the kidneys was increased. And through renal pathology analysis, the compound Aila tablets improved the renal damage caused by diabetic nephropathy in rats. The above results show that the compound Aila tablets have a significant improvement effect on diabetic nephropathy and can be used as a drug for the treatment of diabetic nephropathy.
[0013] The use of the compound Aila tablets described in the present invention in the preparation of drugs for treating diabetic nephropathy has been shown through experiments to have a significant effect on the treatment of diabetic kidneys, providing a new approach for the treatment of diabetic nephropathy, and having important significance and value for clarifying the clinical indications of the compound Aila tablets, and having important significance for the development and utilization of Uyghur medicine resources. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is a graph showing the effect of the compound Aila tablets of the present invention on the body weight of diabetic nephropathy rats;
[0015] Figure 2 This is a graph showing the effect of the compound Aila tablets of the present invention on fasting blood glucose in rats with diabetic nephropathy;
[0016] Figure 3 This is a graph showing the effect of the compound Aila tablets of the present invention on the creatinine content in the blood of diabetic nephropathy rats;
[0017] Figure 4 This is a graph showing the effect of the compound Aila tablets of the present invention on the urea nitrogen content in the blood of diabetic nephropathy rats;
[0018] Figure 5This is a graph showing the effect of the compound Aila tablets of the present invention on the uric acid content in the blood of diabetic nephropathy rats;
[0019] Figure 6 This is a graph showing the effect of the compound Aila tablets of the present invention on the kidney weight ratio of diabetic nephropathy rats;
[0020] Figure 7 This is a graph showing the effect of the compound Aila tablets of the present invention on the total cholesterol content in the blood of diabetic nephropathy rats;
[0021] Figure 8 This is a graph showing the effect of the compound Aila tablets of the present invention on the triglyceride content in the blood of diabetic nephropathy rats;
[0022] Fig. 9 This is a graph showing the effect of the compound Aila tablets of the present invention on the reduced glutathione content in the kidneys of diabetic nephropathy rats;
[0023] Fig.10 This is a graph showing the effect of the compound Aila tablets of the present invention on the content of superoxide dismutase in the kidneys of diabetic nephropathy rats;
[0024] Fig.11 This is a graph showing the effect of the compound Aila tablets of the present invention on the catalase content in the kidneys of diabetic nephropathy rats;
[0025] Fig.12 This is a graph showing the effect of the compound Aila tablets of the present invention on the content of malondialdehyde in the kidneys of rats with diabetic nephropathy;
[0026] Fig.13 This is a graph showing the effect of the compound Aila tablets of the present invention on renal pathological staining (HE staining) of diabetic nephropathy rats. DETAILED DESCRIPTION
[0027] The present invention is described in detail below in conjunction with embodiments, but is not limited to the given embodiments.
[0028] Example 1
[0029] The preparation method of the compound Aila tablets is as follows:
[0030] a. According to the formula in patent 201610365729.8, weigh the raw medicinal materials of anacardia root, Bletilla striata, Epimedium, Rhodiola rosea, Cuscuta australis, Polygonatum odoratum, Lycium barbarum and cinnamon, and use 16 times the amount of 50% ethanol for heating and reflux extraction once, extract for a total of 2h, and collect the extract;
[0031] b. The extract in step a was filtered through a 120-mesh stainless steel mesh, and the filtrate was concentrated under reduced pressure at a temperature of 60°C, -0.08MPa, to a relative density of 1.1, and then transferred to a vacuum drying oven at a temperature of 60°C, -0.08MPa to obtain an extract, which was then crushed by a universal grinder and passed through a 100-mesh oscillating sieve to obtain a subdivided extract;
[0032] c. The saffron was crushed and mixed with the extract powder obtained in step b through a 100-mesh sieve to obtain a compound Aila tablet extract;
[0033] d. The Aila tablet extract obtained in step c is prepared into tablets with povidone K90 as a binder and cross-linked sodium carboxymethyl cellulose as a disintegrant to obtain compound Aila tablets.
[0034] Example 2
[0035] Use of the compound Aila tablets in the preparation of drugs for treating diabetic nephropathy, and efficacy experiments in treating diabetic nephropathy in animals:
[0036] Experimental methods:
[0037] The obtained compound Aila tablet extract was used for animal experiment efficacy evaluation:
[0038] Experimental animal husbandry:
[0039] Male Sprague Dawley (SD) rats, 8-10 weeks old, weighing 180-220 g, with a specific pathogen-free grade, were purchased from the Animal Experiment Center of Xinjiang Medical University and raised in an SPF-level barrier environment. Production license number: SCXK (New)
[0040] 2018-0002, use license number: SYXK (new) 2018-0003, ambient temperature 22 ± 3 °C, relative humidity 40%-60%, light intensity maintained at 12 h per day, day and night alternation, animals free access to food and water, the experimental protocol was approved by the Experimental Animal Ethics Committee of Xinjiang Medical University (ethics number: IACUC-JT-20230321-06);
[0041] Establishment of animal diabetic nephropathy model:
[0042] After 1 week of adaptive feeding, 85 male SD rats were randomly divided into a control group and a model group, including 75 rats in the model group and 10 rats in the control group. The model group was fed with a high-sugar and high-fat diet, and the control group was fed with a normal diet. After four weeks of feeding, the rats were fasted and deprived of water for 12 hours in advance, and streptozotocin (STZ) was dissolved in a sodium citrate buffer with a pH value of 4.4 at a dose of 35 mg / kg to prepare a 1% concentration of streptozotocin (STZ) solution for intraperitoneal injection of rats. Tail vein blood was collected 72 hours after injection, and fasting blood glucose was measured with a blood glucose meter. When the fasting blood glucose value was ≥16.7mmol / L for three consecutive days, and the urine volume and water intake increased significantly, the model was successfully established.
[0043] Experimental animal grouping, drug administration and experimental plan:
[0044] The model rats were randomly divided into model (MG) group, positive drug (MET) group (metformin 200 mg / kg), low-dose ALP L (80 mg / kg), medium-dose ALP M (160 mg / kg) and high-dose ALP H (320 mg / kg) group; oral gavage was performed once a day, and the control group (CG) was given the corresponding volume of CMC Na aqueous solution;
[0045] The drug was administered for 10 consecutive weeks, and the fasting blood glucose of the rats was tested, weighed and recorded every week. After the experiment, blood was collected from the abdominal aorta of the rats and centrifuged for blood index detection. The kidneys were weighed, one kidney was placed in neutral formalin for pathological experiments, and the other kidney was quickly frozen in a -80℃ refrigerator for kidney-related index detection.
[0046] Experimental results:
[0047] The results of compound Aila tablets and positive drug metformin in the treatment of diabetic nephropathy are as follows:
[0048] like Figure 1 As shown: Compared with the model group, Compound Aila Tablets can improve the weight loss of rats caused by diabetic nephropathy and increase the weight of rats; Figure 2 As shown in the results, compared with the model group, Compound Aila Tablets can alleviate the increase of blood sugar level in rats caused by diabetic nephropathy and reduce blood sugar level; in terms of rat kidney biochemical indicators, such as Figure 3 , 4 As shown in Figure 5, Compound Aila Tablets can significantly reduce the elevated creatinine, urea nitrogen and uric acid levels in rats due to diabetic nephropathy; Figure 6 As shown in the results, Compound Aila Tablets can significantly reduce the increased kidney weight ratio in rats due to diabetic nephropathy; Figure 7 , 8 As shown in the results, the total cholesterol and triglyceride levels in the blood of rats with diabetic nephropathy were significantly increased, and Compound Aila Tablets could significantly reduce these two indicators; Fig. 9 , 10 As shown in Figures 11, the levels of reduced glutathione, superoxide dismutase, and catalase in the kidneys of diabetic nephropathy rats were significantly reduced, and the level of malondialdehyde was significantly increased; Fig.12 Compound Aila tablets can significantly increase the levels of reduced glutathione, superoxide dismutase and catalase in the kidney, reduce the content of malondialdehyde in the kidney, and enhance the kidney's antioxidant capacity; Fig.13 As shown, Compound Aila Tablets can alleviate glomerular and tubular lesions in rat kidneys caused by diabetic nephropathy.
[0049] In summary, Compound Aila Tablets are effective in treating diabetic nephropathy.
Claims
1. Use of a compound Aila tablet in the preparation of a medicine for treating diabetic nephropathy.
Citation Information
Patent Citations
Yang-tonifying compound Uygur medicine preparation and preparation method and application thereof
CN105816682A
